FDA Approves New RAS Inhibitor for Pancreatic Cancer
The FDA has approved Rasonque, a targeted therapy for advanced pancreatic cancer, months ahead of schedule, delivering a novel treatment option after months of regulatory review.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day